<p>萬基遺傳公司（NASDAQ:MYGN - 獲取免費報告）目前獲得了 14 位分析師的共識評級為 “持有”，Marketbeat Ratings 報告稱。兩位投資分析師給予該股票賣出評級，八位給予持有評級，四位給予買入評級。在過去一年中，發佈報告的經紀人對該股票的平均 12 個月目標價格為 10.50 美元。</p>
<p>獲取 <strong>Myriad Genetics</strong> 警報：</p>
<ul>
<li>萬基遺傳因遺傳性癌症檢測而股價飆升</li>
</ul>
<p>MYGN 已成為多份研究報告的主題。Piper Sandler 將萬基遺傳的目標價格從 9.00 美元下調至 8.50 美元，並在 11 月 11 日的報告中對該公司給予 “超配” 評級。Weiss Ratings 在週一的報告中重申了對萬基遺傳股票的 “賣出（d-）” 評級。Cowen 在 11 月 4 日的報告中重申了對萬基遺傳股票的 “持有” 評級。瑞銀集團在 11 月 4 日的研究報告中將萬基遺傳股票的目標價格從 6.00 美元上調至 8.00 美元，並給予該股票 “中性” 評級。最後，富國銀行在 11 月 5 日的報告中將萬基遺傳股票的目標價格從 6.00 美元上調至 6.50 美元，並給予該公司 “等權重” 評級。</p>
<p><strong>獲取我們關於 MYGN 的最新報告</strong></p>
<h2>機構資金流入和流出</h2>
<ul>
<li>精確科學公司為投資者提供了他們所希望的</li>
</ul>
<p>一些機構投資者和對沖基金最近調整了對 MYGN 的持股。先鋒集團在第一季度將其在萬基遺傳的股份增加了 0.7%。先鋒集團目前擁有 10,667,755 股該公司股票，價值 94,623,000 美元，此前在上個季度增持了 76,712 股。Glenview Capital Management LLC 在第二季度將其在萬基遺傳的持股增加了 17.6%。Glenview Capital Management LLC 目前擁有 4,587,407 股該公司股票，價值 24,359,000 美元，此前在上個季度增持了 687,857 股。Jacobs Levy Equity Management Inc. 在第三季度將其在萬基遺傳的持股增加了 157.0%。Jacobs Levy Equity Management Inc. 目前擁有 2,442,912 股該公司股票，價值 17,662,000 美元，此前在上個季度增持了 1,492,405 股。Qube Research &amp; Technologies Ltd 在第二季度將其在萬基遺傳的股份增加了 44.7%。Qube Research &amp; Technologies Ltd 目前擁有 2,051,588 股該公司股票，價值 10,894,000 美元，此前在上個季度增持了 633,439 股。最後，Connor Clark &amp; Lunn Investment Management Ltd. 在第二季度將其在萬基遺傳的持股增加了 50.5%。Connor Clark &amp; Lunn Investment Management Ltd. 目前擁有 1,387,832 股該公司股票，價值 7,369,000 美元，此前在上個季度增持了 465,921 股。對沖基金和其他機構投資者持有該公司 99.02% 的股票。</p>
<h2>萬基遺傳股票下跌 1.6%</h2>
<p>NASDAQ:MYGN 的股票在週三開盤時為 6.88 美元。該公司的市值為 6.4128 億美元，市盈率為-1.59，貝塔值為 1.81。該公司的 50 日簡單移動平均為 7.35 美元，200 日簡單移動平均為 6.37 美元。萬基遺傳的 1 年最低價為 3.76 美元，1 年最高價為 15.47 美元。該公司的債務與股本比率為 0.32，流動比率為 2.33，速動比率為 2.12。</p>
<p>萬基遺傳（NASDAQ:MYGN - 獲取免費報告）最後一次發佈財報是在 1 月 16 日，週二。該公司報告本季度每股收益為（0.19 美元）。萬基遺傳的股本回報率為-7.11%，淨利潤率為-48.53%。該公司在本季度的收入為 1.564 億美元。萬基遺傳已將其 2023 財年的指導目標設定為每股收益（0.33）-（0.28）美元。分析師平均預測萬基遺傳在當前年度的每股收益為-0.3 美元。</p>
<h2>關於萬基遺傳</h2>
<p>（獲取免費報告）</p>
<p>萬基遺傳公司是一家基因檢測和精準醫療公司，在美國和國際上開發基因檢測。該公司提供用於腫瘤學、女性健康和藥物基因組學的分子診斷測試。它還提供 MyRisk 遺傳性癌症檢測，這是一種評估遺傳性癌症風險的 DNA 測序測試；BRACAnalysis CDx 胚系伴隨診斷測試，這是一種幫助確定轉移性乳腺癌、卵巢癌、轉移性胰腺癌和轉移性前列腺癌患者治療方案的 DNA 測序測試，適用於具有有害或疑似有害胚系 BRCA 變異的患者；以及 MyChoice CDx 伴隨診斷測試，這是一種確定卵巢癌患者同源重組缺陷狀態的腫瘤測試。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過萬基遺傳</li>
<li>3 只沃倫·巴菲特在動盪時期必買的股票</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
<li>深入分析買賣差價</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的買入機會</li>
<li>3 只股票可以保護你的投資組合免受冠狀病毒傳播的影響</li>
<li>RTX 在國防訂單激增的情況下飆升至歷史新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg"/></p>
<p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在萬基遺傳嗎？</h2>
<p>在你考慮萬基遺傳之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而萬基遺傳並不在名單上。</p>
<p>雖然萬基遺傳目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

萬基遺傳

<p>萬基遺傳（Myriad Genetics, Inc.）（納斯達克代碼：MYGN）獲得了 14 位分析師的共識 “持有” 評級，評級從賣出到買入不等。平均目標價為 10.50 美元。機構投資者已調整其持股，持有的股份發生了顯著變化。該股票開盤價為 6.88 美元，市值為 6.4128 億美元。公司報告的每股收益（EPS）為負值（-0.19 美元），並將 2023 財年的指導目標設定為（-0.33）至（-0.28）美元的每股收益。萬基遺傳提供腫瘤學及其他醫學領域的基因檢測</p>

<p>Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.50.</p>
<div class="lb-trans"><p>萬基遺傳公司（NASDAQ:MYGN - 獲取免費報告）目前獲得了 14 位分析師的共識評級為 “持有”，Marketbeat Ratings 報告稱。兩位投資分析師給予該股票賣出評級，八位給予持有評級，四位給予買入評級。在過去一年中，發佈報告的經紀人對該股票的平均 12 個月目標價格為 10.50 美元。</p>
</div><p>Get <strong>Myriad Genetics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Myriad Genetics</strong> 警報：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>萬基遺傳因遺傳性癌症檢測而股價飆升</li>
</ul>
</div><p>MYGN has been the subject of a number of research reports. Piper Sandler lowered their price target on Myriad Genetics from $9.00 to $8.50 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, November 11th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Myriad Genetics in a report on Monday. Cowen reiterated a &#34;hold&#34; rating on shares of Myriad Genetics in a report on Tuesday, November 4th. UBS Group upped their price target on shares of Myriad Genetics from $6.00 to $8.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, November 4th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Myriad Genetics from $6.00 to $6.50 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 5th.</p>
<div class="lb-trans"><p>MYGN 已成為多份研究報告的主題。Piper Sandler 將萬基遺傳的目標價格從 9.00 美元下調至 8.50 美元，並在 11 月 11 日的報告中對該公司給予 “超配” 評級。Weiss Ratings 在週一的報告中重申了對萬基遺傳股票的 “賣出（d-）” 評級。Cowen 在 11 月 4 日的報告中重申了對萬基遺傳股票的 “持有” 評級。瑞銀集團在 11 月 4 日的研究報告中將萬基遺傳股票的目標價格從 6.00 美元上調至 8.00 美元，並給予該股票 “中性” 評級。最後，富國銀行在 11 月 5 日的報告中將萬基遺傳股票的目標價格從 6.00 美元上調至 6.50 美元，並給予該公司 “等權重” 評級。</p>
</div><p><strong>Get Our Latest Report on MYGN</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 MYGN 的最新報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>精確科學公司為投資者提供了他們所希望的</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of MYGN. Vanguard Group Inc. boosted its stake in Myriad Genetics by 0.7% in the first quarter. Vanguard Group Inc. now owns 10,667,755 shares of the company's stock valued at $94,623,000 after acquiring an additional 76,712 shares in the last quarter. Glenview Capital Management LLC boosted its position in shares of Myriad Genetics by 17.6% in the 2nd quarter. Glenview Capital Management LLC now owns 4,587,407 shares of the company's stock worth $24,359,000 after purchasing an additional 687,857 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Myriad Genetics by 157.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company's stock valued at $17,662,000 after buying an additional 1,492,405 shares in the last quarter. Qube Research &amp; Technologies Ltd raised its stake in Myriad Genetics by 44.7% in the second quarter. Qube Research &amp; Technologies Ltd now owns 2,051,588 shares of the company's stock valued at $10,894,000 after buying an additional 633,439 shares during the last quarter. Finally, Connor Clark &amp; Lunn Investment Management Ltd. boosted its holdings in Myriad Genetics by 50.5% in the second quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 1,387,832 shares of the company's stock worth $7,369,000 after acquiring an additional 465,921 shares in the last quarter. Hedge funds and other institutional investors own 99.02% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近調整了對 MYGN 的持股。先鋒集團在第一季度將其在萬基遺傳的股份增加了 0.7%。先鋒集團目前擁有 10,667,755 股該公司股票，價值 94,623,000 美元，此前在上個季度增持了 76,712 股。Glenview Capital Management LLC 在第二季度將其在萬基遺傳的持股增加了 17.6%。Glenview Capital Management LLC 目前擁有 4,587,407 股該公司股票，價值 24,359,000 美元，此前在上個季度增持了 687,857 股。Jacobs Levy Equity Management Inc. 在第三季度將其在萬基遺傳的持股增加了 157.0%。Jacobs Levy Equity Management Inc. 目前擁有 2,442,912 股該公司股票，價值 17,662,000 美元，此前在上個季度增持了 1,492,405 股。Qube Research &amp; Technologies Ltd 在第二季度將其在萬基遺傳的股份增加了 44.7%。Qube Research &amp; Technologies Ltd 目前擁有 2,051,588 股該公司股票，價值 10,894,000 美元，此前在上個季度增持了 633,439 股。最後，Connor Clark &amp; Lunn Investment Management Ltd. 在第二季度將其在萬基遺傳的持股增加了 50.5%。Connor Clark &amp; Lunn Investment Management Ltd. 目前擁有 1,387,832 股該公司股票，價值 7,369,000 美元，此前在上個季度增持了 465,921 股。對沖基金和其他機構投資者持有該公司 99.02% 的股票。</p>
</div><h2>Myriad Genetics Stock Down 1.6%</h2>
<div class="lb-trans"><h2>萬基遺傳股票下跌 1.6%</h2>
</div><p>Shares of NASDAQ:MYGN opened at $6.88 on Wednesday. The firm has a market capitalization of $641.28 million, a PE ratio of -1.59 and a beta of 1.81. The business has a 50 day simple moving average of $7.35 and a two-hundred day simple moving average of $6.37. Myriad Genetics has a 1 year low of $3.76 and a 1 year high of $15.47. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.33 and a quick ratio of 2.12.</p>
<div class="lb-trans"><p>NASDAQ:MYGN 的股票在週三開盤時為 6.88 美元。該公司的市值為 6.4128 億美元，市盈率為-1.59，貝塔值為 1.81。該公司的 50 日簡單移動平均為 7.35 美元，200 日簡單移動平均為 6.37 美元。萬基遺傳的 1 年最低價為 3.76 美元，1 年最高價為 15.47 美元。該公司的債務與股本比率為 0.32，流動比率為 2.33，速動比率為 2.12。</p>
</div><p>Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its earnings results on Tuesday, January 16th. The company reported ($0.19) earnings per share for the quarter. Myriad Genetics had a negative return on equity of 7.11% and a negative net margin of 48.53%.The business had revenue of $156.40 million during the quarter. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. On average, equities analysts predict that Myriad Genetics will post -0.3 EPS for the current year.</p>
<div class="lb-trans"><p>萬基遺傳（NASDAQ:MYGN - 獲取免費報告）最後一次發佈財報是在 1 月 16 日，週二。該公司報告本季度每股收益為（0.19 美元）。萬基遺傳的股本回報率為-7.11%，淨利潤率為-48.53%。該公司在本季度的收入為 1.564 億美元。萬基遺傳已將其 2023 財年的指導目標設定為每股收益（0.33）-（0.28）美元。分析師平均預測萬基遺傳在當前年度的每股收益為-0.3 美元。</p>
</div><h2>About Myriad Genetics</h2>
<div class="lb-trans"><h2>關於萬基遺傳</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.</p>
<div class="lb-trans"><p>萬基遺傳公司是一家基因檢測和精準醫療公司，在美國和國際上開發基因檢測。該公司提供用於腫瘤學、女性健康和藥物基因組學的分子診斷測試。它還提供 MyRisk 遺傳性癌症檢測，這是一種評估遺傳性癌症風險的 DNA 測序測試；BRACAnalysis CDx 胚系伴隨診斷測試，這是一種幫助確定轉移性乳腺癌、卵巢癌、轉移性胰腺癌和轉移性前列腺癌患者治療方案的 DNA 測序測試，適用於具有有害或疑似有害胚系 BRCA 變異的患者；以及 MyChoice CDx 伴隨診斷測試，這是一種確定卵巢癌患者同源重組缺陷狀態的腫瘤測試。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Myriad Genetics</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li>
<li>A Deeper Look at Bid-Ask Spreads</li>
<li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>RTX Surges to Record Highs as Defense Orders Explode</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過萬基遺傳</li>
<li>3 只沃倫·巴菲特在動盪時期必買的股票</li>
<li>AI 芯片離不開這兩家被低估的科技巨頭</li>
<li>深入分析買賣差價</li>
<li>為什麼台灣半導體的 6.5% 下跌可能是一個明智的買入機會</li>
<li>3 只股票可以保護你的投資組合免受冠狀病毒傳播的影響</li>
<li>RTX 在國防訂單激增的情況下飆升至歷史新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MYGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Myriad Genetics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在萬基遺傳嗎？</h2>
</div><p>Before you consider Myriad Genetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮萬基遺傳之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而萬基遺傳並不在名單上。</p>
</div><p>While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然萬基遺傳目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

萬基遺傳公司（NASDAQ: MYGN）被券商給予平均 “持有” 評級